CELLBXHEALTH PLC (ANPCF) 股價（美元）

ANGLE is a world leading liquid biopsy company with pioneering products in cancer diagnostics. ANGLEs lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumour cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalised cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. FDA clearance in metastatic breast cancer is in process with a 400 patient study. ANGLE is also undertaking clinical studies, the first one of which is in Ovarian Cancer for a clinical application to triage women having surgery for an abnormal pelvic mass to identify those with ovarian cancer. 200 patient clinical studies in both Europe and the US have reported positive headline data with ROC-AUC of 95.1% and the test is being optimized before moving to validation studies. ANGLE also has a novel multiplex diagnostic tool called Ziplex for the analysis of DNA, RNA and proteins